How drug naming complicates pharma data curation and competitive intelligence

One drug, seven names: the hidden complexity of pharmaceutical competitive intelligence data

In March 2018, Celgene closed a $9 billion acquisition of Juno Therapeutics, gaining full rights to a CAR T-cell therapy program then known as JCAR017. A year later, Bristol Myers Squibb acquired Celgene for $74 billion, and the asset came with it. By 2021, the FDA had approved it under a name most people in the industry had never encountered during its development: lisocabtagene maraleucel, sold commercially as Breyanzi.^{1, 2, 3, 4}

Today, Breyanzi is the only CAR T-cell therapy approved for five different cancer types. It’s also a precise illustration of why building a reliable pharmaceutical competitive intelligence database is genuinely hard – and why the difference between curated intelligence and raw data aggregation matters for every decision that relies on it.⁵

Why drug naming makes pharmaceutical data so difficult

As a drug moves from an academic lab through a startup, an acquirer and a global pharma company, it accumulates identifiers at every stage. Each one is correct in the context where it appears. Each surfaces in different source types. None of them automatically connect to the others.

For lisocabtagene maraleucel, those identifiers include:

Lisocabtagene maraleucel – the International Nonproprietary Name (INN), the standard in regulatory filings and peer-reviewed journals^1, ⁶
Breyanzi – the brand name in commercial communications and payer coverage policies⁷
Liso-cel – the shorthand that became standard at medical conferences and in clinical literature⁸
JCAR017 – Juno Therapeutics’ original research code, embedded in early trial registries and development publications^{2, 9}
BMS-986387 – the pipeline identifier assigned after the Celgene acquisition, appearing in company and regulatory submissions
Anti-CD19 CAR T-cell therapy – the descriptive term used in early patents and preclinical research
SCRI-CAR19v1 – a construct name used in investigator-led translational studies

A biopharma analyst searching “JCAR017” and a colleague searching “Breyanzi” are researching the same asset. Making that connection requires more than keyword matching – it requires an entity resolution framework built and maintained by people who understand how drug development actually works.

Company names change just as fast as drug names

The ownership chain behind Breyanzi creates a second layer of resolution complexity, because each company in that chain appears differently depending on when and where a document was written.

Juno Therapeutics, the originator, appears in primary sources as Juno Therapeutics, Juno Therapeutics Inc., Juno Therapeutics LLC, and Juno (Celgene), with variations driven by lifecycle stage and corporate changes. Celgene, which completed the Juno acquisition in early 2018, is indexed across sources as Celgene, Celgene Corporation, Celgene Corp., Celgene Inc., Celgene/BMS, and the ticker CELG. Bristol Myers Squibb — the current owner following its $74 billion acquisition of Celgene in 2019 — appears as Bristol Myers Squibb Company, Bristol-Myers Squibb, and BMS.^4, ^{10, 11,} ¹²

Tracing who developed what, when and under which corporate entity requires resolving drug identifiers, company names and ownership timelines at the same time. A missed match at any of those three layers misattributes a program, erases competitive history, or miscounts an acquisition’s asset value.

Multiple approved indications, dozens of indication synonyms

The clinical complexity of a single asset adds a third layer. Lisocabtagene maraleucel has received FDA approval across five indications since 2021:^{1, 5}

Large B-cell lymphoma (initial approval, February 2021)
Chronic lymphocytic leukemia / Small lymphocytic lymphoma (March 2024)⁸
Follicular lymphoma (May 2024)⁶
Mantle cell lymphoma (May 2024)⁸
Marginal zone lymphoma (December 2025)⁵

Each of these indications carries its own vocabulary in the medical literature. Diffuse large B-cell lymphoma appears as DLBCL, DLBCL NOS and aggressive non-Hodgkin lymphoma. Follicular lymphoma appears as FL, FNHL, and small follicular center cell lymphoma. Marginal zone lymphoma appears as MZL, MALT lymphoma and mucosa-associated lymphoid tissue lymphoma across different sources.

Adding another wrinkle: not every source covers every indication. Early journals focus on the original DLBCL program. Regulatory submissions reflect the approved population at the time of filing. Conference abstracts describe trial cohorts that map to indications approved years later. The complete clinical picture only exists when all of those fragments are connected across time.

What curated pharmaceutical intelligence looks like at scale

Cortellis Competitive Intelligence tracks 101,000+ pipeline drugs and 32,000+ drugs in early research, with coverage spanning 3,000+ diseases, 6.9M+ patents and 316,000+ company profiles across the full drug development lifecycle. That scale is only useful when the underlying data is correctly linked.¹³

Every record in Cortellis reflects a curation process built around three foundations. Subject matter experts review and validate sources, resolving ambiguities that automated aggregation can’t catch. Editorial standards are applied consistently so that self-reported data from company pipelines is held to the same reliability as peer-reviewed journal data. And ontological indexing maps every alias, research code, brand name and descriptive term to a single authoritative entity — across 700+ peer-reviewed journals, 100+ scientific conferences, 7 major global patent offices and major regulatory agencies including the FDA, EMA, PMDA, and TGA.

Critically, the historical record is preserved. An identifier current in 2016 still connects to the approved product in 2026. A company absorbed through two acquisitions still carries its full development history forward. A search for “MALT lymphoma” returns the same results as a search for “marginal zone B-cell lymphoma.”

The liso-cel story isn’t an edge case. With 101,000+ tracked programs in the Cortellis database, it’s closer to the rule.

Learn more about how Cortellis Competitive Intelligence helps pharma and biotech teams move from reactive tracking to proactive strategic foresight: Cortellis Competitive Intelligence & Analytics | Clarivate

References

S. Food and Drug Administration. (2026, March 11). BREYANZI. Retrieved from www.fda.gov: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi
S. Securities Exchange Commission. (2018, March 6). CELGENE COMPLETES ACQUISITION OF JUNO THERAPEUTICS, INC.,. Retrieved from www.sec.gov: https://www.sec.gov/Archives/edgar/data/816284/000114420418012947/tv487762_99-2.htm
American Pharmaceutical Review. (2018, March 6). Celgene Completes Acquisition of Juno Therapeutics. Retrieved from https://www.americanpharmaceuticalreview.com/1315-News/347745-Celgene-Completes-Acquisition-of-Juno-Therapeutics/
Schubert, C. (2019, January 10). Bristol-Myers Squibb’s $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert. Retrieved from GeekWire: https://www.geekwire.com/2019/bristol-myers-squibbs-74b-acquisition-juno-parent-celgene-puts-seattle-biotech-world-alert/
Bristol Myers Squibb. (2025, December 4). Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL). Retrieved from news.bms.com: https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibbs-Breyanzi-Approved-by-the-U-S–FDA-as-the-First-and-Only-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Marginal-Zone-Lymphoma-MZL/default.aspx
National Institutes of Health. (2025, August 22). FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma. Retrieved from NIH National Library of Medicine: https://pmc.ncbi.nlm.nih.gov/articles/PMC12369282/
Bristol Myers Squibb. (n.d.). Breyanzi. Retrieved from www.breyanzi.com: https://www.breyanzi.com/
American Association for Cancer Research. (2024). Lisocabtagene Maraleucel Approved for Aggressive Lymphoma. Retrieved from www.aacr.org: https://www.aacr.org/patients-caregivers/progress-against-cancer/lisocabtagene-maraleucel-approved-for-aggressive-lymphoma/
Taylor, P. (2018, January 22). Celgene confirms $9B Juno buyout, sees $3B sales for JCAR017. Retrieved from Fierce Biotech: https://www.fiercebiotech.com/biotech/celgene-confirms-9bn-juno-buyout-sees-3bn-sales-for-jcar017
Inman, S. (2018, January 22). Celgene Acquiring Juno Therapeutics for $9 Billion. Retrieved from OncLive: https://www.onclive.com/view/celgene-acquires-juno-therapeutics-for-9-billion
S. Securities Exchange Commission. (2018, January 22). CELGENE CORPORATION TO ACQUIRE JUNO THERAPEUTICS, INC., ADVANCING GLOBAL LEADERSHIP IN CELLULAR IMMUNOTHERAPY. Retrieved from www.sec.gov: https://www.sec.gov/Archives/edgar/data/816284/000114420418002935/tv483707_ex99-2.htm
JUNO THERAPEUTICS, INC.,. Retrieved from www.sec.gov: https://www.sec.gov/Archives/edgar/data/816284/000114420418012947/tv487762_99-2.htm